MREO news

Latest 1 stories · newest Nov 9, 2026

MREO

Mereo BioPharma Reports Q3 2026 Financial Results, Highlights setrusumab and alvelestat progress

Mereo reported $26.1 million in cash available through late-2027 despite ongoing late-stage clinical program challenges. The company provided updates on regulatory pathways for setrusumab in osteogenesis imperfecta and alvelestat in alpha-1 antitrypsin deficiency.

Earnings|Other Nov 9, 2026 sentiment 0.00 SEC filing ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same MREO feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/MREO/newsSTART FREE